What We Do / Investment Banking / Consumer Health | 2H 2024 Market Review
Consumer Health | 2H 2024 Market Review
Investment Banking | Healthcare
Alantra aims to foster knowledge sharing and collaboration across the Consumer Health (CH) universe. We publish this report to reflect what we see and hear in the market.
In this report, we delve into the transformative role of Artificial Intelligence (AI) with an exclusive interview featuring Alfred Whitehead. His insights illuminate how Large Language Models are revolutionizing personalized marketing strategies.
Building on our previous findings, we continue to explore the escalating interest in OTC switches, with a focus on prominent examples like Opill and Narcan. Our analysis extends to examining evolving consumer behaviors in retail environments and strategic insights into distribution channels for CH and Prescription (Rx) products.
Furthermore, our report examines the delayed adoption of natural OTC products in North America. Globally, we provide a thorough examination of current trends and strategic trajectories within the OTC market, with a particular emphasis on the evolving CH landscape in China.

Download Form
Consumer & Healthcare Team
-
Rusty Ray
Managing Partner
United States of America
-
Matthew Wiseman
Partner
United Kingdom
-
Joshua Garver
Managing Director
United States of America
-
Charles Lanceley
Managing Director
United Kingdom
-
Franck Noat
Managing Partner
France
-
Justin Crowther
Managing Director
United Kingdom
-
Guillermo Arbolí
Managing Partner
Spain
-
Christopher Jobst
Partner
Germany
-
Frederic Laurier
Managing Director
United States of America
-
Fabrice Scheer
Managing Partner
France
-
Gianni Casanova
Partner
Brazil; Chile
-
Jonas Bauréus
Managing Partner
Nordics
-
Michael Maag
Managing Partner
Switzerland